COMP <GO>
CHE vs MRK // FORWARD P/E MULTIPLE
Chemed Corp (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CHE 6
— MRK 8
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $534.72 (-1.33%) • MKT CAP: $7.08B
forward-pe
140.0x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CHE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CHE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 32.50% | 74.80% | -42.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 23.40% | 20.70% | +2.70 | CHE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.5x | 15.3x | +3.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 3.42% | +1.18 | CHE | /fcf-yield <GO> |
| Operating Margin | 13.40% | 34.30% | -20.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.10% | -28.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 65.30% | 1.30% | +64.00 | CHE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.45% | 2.26% | -1.81 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.68 | 5.19 | +7.49 | CHE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.8 | 56.9 | +4.93 | CHE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | CHE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 140.0x | 18.4x | +121.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.08B | $361.02B | -$353.94B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CHE REV | MRK REV | CHE GROSS % | MRK GROSS % | CHE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $65.01B | 32.5% | 74.8% | $325.5M | $12.36B |
| FY 2024 | $1.53B | $64.17B | -3.0% | 76.3% | $368.0M | $18.10B |
| FY 2023 | $1.32B | $60.12B | 44.0% | 44.0% | $271.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CHE // BETA 1.08
MRK // BETA 0.92